Skip to main content
Journal ArticleOPEN ACCESS

Semaglutide: a new GLP‐1 analogue for type 2 diabetes

  • Chaplin S
Prescriber (2019) 30(8) 32-34
DOI: 10.1002/psb.1784
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Semaglutide (Ozempic) is a new once‐weekly glucagon‐like peptide‐1 (GLP‐1) analogue for the treatment of type 2 diabetes. This article examines its efficacy, adverse effects and place in therapy.

Cite

CITATION STYLE

APA

Chaplin, S. (2019). Semaglutide: a new GLP‐1 analogue for type 2 diabetes. Prescriber, 30(8), 32–34. https://doi.org/10.1002/psb.1784

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free